The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group.
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D003327:Coronary Disease / Q000188:drug therapy* / Q000517:prevention & control; D003918:Dextrothyroxine / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis; D009539:Nicotinic Acids / Q000627:therapeutic use; D010919:Placebos; D012008:Recurrence; D012964:Sodium; D013997:Time Factors
D000924:Anticholesteremic Agents; D004966:Estrogens, Conjugated (USP); D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D009539:Nicotinic Acids; D010919:Placebos; D003918:Dextrothyroxine; D012964:Sodium; D002994:Clofibrate